126 related articles for article (PubMed ID: 37663423)
21. Reexamining the Ethics of Human Germline Editing in the Wake of Scandal.
Meagher KM; Allyse MA; Master Z; Sharp RR
Mayo Clin Proc; 2020 Feb; 95(2):330-338. PubMed ID: 32029087
[TBL] [Abstract][Full Text] [Related]
22. Ethical and regulatory issues in human gene editing: Chinese perspective.
Lei R; Qiu R
Biotechnol Appl Biochem; 2020 Nov; 67(6):880-891. PubMed ID: 33011985
[TBL] [Abstract][Full Text] [Related]
23. Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy.
Schleidgen S; Dederer HG; Sgodda S; Cravcisin S; Lüneburg L; Cantz T; Heinemann T
BMC Med Ethics; 2020 Sep; 21(1):87. PubMed ID: 32912206
[TBL] [Abstract][Full Text] [Related]
24. CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues.
Piergentili R; Del Rio A; Signore F; Umani Ronchi F; Marinelli E; Zaami S
Cells; 2021 Apr; 10(5):. PubMed ID: 33919194
[TBL] [Abstract][Full Text] [Related]
25. Researchers views about perceived harms and benefits of gene editing: A study from the MENA region.
Abuhammad S; Khabour OF; Alzoubi KH
Heliyon; 2021 Apr; 7(4):e06860. PubMed ID: 33997394
[TBL] [Abstract][Full Text] [Related]
26. Ethical considerations of preconception and prenatal gene modification in the embryo and fetus.
Mattar CNZ; Labude MK; Lee TN; Lai PS
Hum Reprod; 2021 Nov; 36(12):3018-3027. PubMed ID: 34665851
[TBL] [Abstract][Full Text] [Related]
27. Gene editing of human embryos is not contrary to human rights law: A reply to Drabiak.
Boggio A; Yotova R
Bioethics; 2021 Nov; 35(9):956-963. PubMed ID: 34453362
[TBL] [Abstract][Full Text] [Related]
28. The versatile electric condition in mouse embryos for genome editing using a three-step square-wave pulse electroporator.
Nakano K; Shimizu Y; Arai T; Kaneko T; Okamura T
Exp Anim; 2022 May; 71(2):214-223. PubMed ID: 34880157
[TBL] [Abstract][Full Text] [Related]
29. Some Ethical Concerns About Human Induced Pluripotent Stem Cells.
Zheng YL
Sci Eng Ethics; 2016 Oct; 22(5):1277-1284. PubMed ID: 26276162
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Genome Editing in Cardiovascular Diseases.
German DM; Mitalipov S; Mishra A; Kaul S
JACC Basic Transl Sci; 2019 Feb; 4(1):122-131. PubMed ID: 30847427
[TBL] [Abstract][Full Text] [Related]
31. Bioethical issues in genome editing by CRISPR-Cas9 technology.
Ayanoğlu FB; Elçin AE; Elçin YM
Turk J Biol; 2020; 44(2):110-120. PubMed ID: 32256147
[TBL] [Abstract][Full Text] [Related]
32. Efficient Generation of Pathogenic A-to-G Mutations in Human Tripronuclear Embryos via ABE-Mediated Base Editing.
Li G; Liu X; Huang S; Zeng Y; Yang G; Lu Z; Zhang Y; Ma X; Wang L; Huang X; Liu J
Mol Ther Nucleic Acids; 2019 Sep; 17():289-296. PubMed ID: 31279230
[TBL] [Abstract][Full Text] [Related]
33. [Development and challenges of gene editing technology].
Liu Y; Xiong Y; Cai Z; Zhang B
Sheng Wu Gong Cheng Xue Bao; 2019 Aug; 35(8):1401-1410. PubMed ID: 31441611
[TBL] [Abstract][Full Text] [Related]
34. Global Governance of Human Genome Editing: What Are the Rules?
Marchant GE
Annu Rev Genomics Hum Genet; 2021 Aug; 22():385-405. PubMed ID: 33667117
[TBL] [Abstract][Full Text] [Related]
35. Public attitudes in the clinical application of genome editing on human embryos in Japan: a cross-sectional survey across multiple stakeholders.
Kobayashi S; Miyoshi T; Kobayashi T; Hayakawa I; Urayama KY; Uchiyama M; Muto K; Takeuchi Y; Taira M; Sago H; Takehara K
J Hum Genet; 2022 Sep; 67(9):541-546. PubMed ID: 35534678
[TBL] [Abstract][Full Text] [Related]
36. Are we ready for genome editing in human embryos for clinical purposes?
Harper JC; Schatten G
Eur J Med Genet; 2019 Aug; 62(8):103682. PubMed ID: 31150829
[TBL] [Abstract][Full Text] [Related]
37. [A new milestone in human embryo editing].
Jordan B
Med Sci (Paris); 2017 May; 33(5):549-554. PubMed ID: 28612733
[TBL] [Abstract][Full Text] [Related]
38. Creation of Cultures Containing Mutations Linked with Cardiovascular Diseases using Transfection and Genome Editing.
Sazonova MA; Ryzhkova AI; Sinyov VV; Sazonova MD; Khasanova ZB; Nikitina NA; Karagodin VP; Orekhov AN; Sobenin IA
Curr Pharm Des; 2019; 25(6):693-699. PubMed ID: 30931844
[TBL] [Abstract][Full Text] [Related]
39. Clinical trials of germline gene editing: The exploitation problem.
Malmqvist E
Bioethics; 2021 Sep; 35(7):688-695. PubMed ID: 34128232
[TBL] [Abstract][Full Text] [Related]
40. Survey on the perception of germline genome editing among the general public in Japan.
Uchiyama M; Nagai A; Muto K
J Hum Genet; 2018 Jun; 63(6):745-748. PubMed ID: 29545588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
